Jmac Enterprises LLC Acquires 900 Shares of Becton, Dickinson and Company $BDX

Jmac Enterprises LLC increased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 36.0% in the second quarter, HoldingsChannel reports. The firm owned 3,400 shares of the medical instruments supplier’s stock after purchasing an additional 900 shares during the period. Jmac Enterprises LLC’s holdings in Becton, Dickinson and Company were worth $586,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of BDX. Brighton Jones LLC boosted its holdings in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares in the last quarter. Versant Capital Management Inc lifted its position in Becton, Dickinson and Company by 27.4% during the 1st quarter. Versant Capital Management Inc now owns 265 shares of the medical instruments supplier’s stock worth $61,000 after acquiring an additional 57 shares during the last quarter. NBC Securities Inc. acquired a new position in Becton, Dickinson and Company during the 1st quarter worth $102,000. Merit Financial Group LLC lifted its position in Becton, Dickinson and Company by 54.3% during the 1st quarter. Merit Financial Group LLC now owns 5,846 shares of the medical instruments supplier’s stock worth $1,339,000 after acquiring an additional 2,058 shares during the last quarter. Finally, HF Advisory Group LLC lifted its position in Becton, Dickinson and Company by 60.4% during the 1st quarter. HF Advisory Group LLC now owns 5,109 shares of the medical instruments supplier’s stock worth $1,170,000 after acquiring an additional 1,924 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $191.43 on Friday. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $54.87 billion, a PE ratio of 34.43, a price-to-earnings-growth ratio of 1.49 and a beta of 0.25. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The firm has a 50-day moving average price of $188.87 and a 200 day moving average price of $187.95.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.28. The firm had revenue of $5.51 billion for the quarter, compared to analysts’ expectations of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio is 74.82%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on BDX. Morgan Stanley boosted their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Royal Bank Of Canada began coverage on shares of Becton, Dickinson and Company in a research report on Thursday, September 25th. They set a “sector perform” rating and a $211.00 target price for the company. Argus boosted their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Wells Fargo & Company boosted their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research report on Friday, August 8th. Finally, Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $205.40.

Insider Activity at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director directly owned 22,226 shares in the company, valued at $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,023 shares of company stock worth $562,036 over the last three months. 0.36% of the stock is owned by insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.